Privacy preference
MEDtalks would like to keep you informed about the content that is most relevant to you. Click
here
for more information.
Yes
No
Back
ESMO 2019 Respons op neo-adjuvant ipilimumab en nivolumab bij het melanoom
Chat with us
, powered by
LiveChat